Replies to post #226857 on Biotech Values

[DewDiligence]

perhaps it's a corollary to Zebra's Law that a reverse-merger company will kill it's original programs...

In general, such programs plainly have little or no value; however, press releases announcing reverse mergers often try to conceal this in order to save face for the management team that is getting the boot (after the merger closes).

[DewDiligence]

KDS.AS +57% on SNY deal:

https://www.globenewswire.com/news-release/2020/07/08/2059024/0/en/Kiadis-licenses-previously-undisclosed-pre-clinical-K-NK-cell-programs-to-Sanofi-with-total-potential-deal-value-of-875-million-plus-royalties.html

Kiadis Pharma N.V…today announces the exclusive license of Kiadis’ previously undisclosed K-NK004 program to Sanofi. The agreement covers Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutic for combination with anti-CD38 monoclonal antibodies, including Sarclisa, Sanofi’s recently approved therapy for patients with multiple myeloma. Additionally, Sanofi has obtained exclusive rights to use Kiadis’ K-NK platform for two undisclosed pre-clinical programs.

As part of the agreement, Kiadis will receive a €17.5 million up front payment and will be entitled to receive up to €857.5 million upon Sanofi’s achievement of preclinical, clinical, regulatory and commercial milestones. Kiadis will also receive up to low double-digit royalties based on commercial sales of approved products resulting from this agreement.